NCT03947346View on ClinicalTrials.gov

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions

Neuroblastoma Survivors

Interventions

OTHER

Urine sample

The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03947346 - Biomarkers of Renal Dysfunction in Neuroblastoma Survivors | Biotech Hunter | Biotech Hunter